WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009062100) MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/062100    International Application No.:    PCT/US2008/082888
Publication Date: 14.05.2009 International Filing Date: 07.11.2008
IPC:
A61K 38/37 (2006.01), A61K 47/48 (2006.01), C07K 14/755 (2006.01)
Applicants: BAXTER INTERNATIONAL INC. [US/US]; One Baxter Parkway Deerfield, IL 60015 (US) (For All Designated States Except US).
BAXTER HEALTHCARE S.A. [CH/CH]; Thurgauerstrasse 130 CH-8152 Glattpark (Opfikon) (CH) (For All Designated States Except US).
SCHWARZ, Hans-Peter [AT/AT]; (AT) (For US Only).
TURECEK, Peter [AT/AT]; (AT) (For US Only)
Inventors: SCHWARZ, Hans-Peter; (AT).
TURECEK, Peter; (AT)
Agent: PARENT, Annette S.; TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834 (US)
Priority Data:
60/986,975 09.11.2007 US
Title (EN) MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE
(FR) FACTEUR VIII ET FACTEUR DE VON WILLEBRAND RECOMBINÉS MODIFIÉS ET PROCÉDÉ D'UTILISATION
Abstract: front page image
(EN)The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.
(FR)L'invention concerne de nouveaux procédés permettant d'augmenter la survie d'une protéine de coagulation en inhibant l'interaction avec un récepteur de clairance. L'invention concerne également des procédés de préparation de compositions qui inhibent les récepteurs de clairance des protéines de coagulation. L'invention concerne également des protéines de coagulation conjuguées, ainsi que des compositions et des formulations les contenant.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)